Tofacitinib

Tofacitinib is an orally administered small-molecule drug of the Janus kinase inhibitor class, a group of targeted immunomodulators often counted among the newer disease-modifying antirheumatic drugs ^[1]. Its molecular formula is C16H20N6O, and it was known during development by the code CP-690550. The compound emerged from a public-private research effort involving the United States National Institutes of Health and Pfizer that began in the 1990s, and it became one of the first JAK inhibitors to reach the market ^[1].

The United States Food and Drug Administration first approved tofacitinib in 2012 for moderate-to-severe rheumatoid arthritis in patients who had responded inadequately to methotrexate ^[1]. Later approvals extended its use to psoriatic arthritis, ulcerative colitis (where it was the first oral JAK inhibitor cleared for the condition), ankylosing spondylitis, and polyarticular-course juvenile idiopathic arthritis. It is available as immediate-release and extended-release tablets and as an oral solution, marketed principally under the brand name Xeljanz, and it is prescription-only across major markets. Following safety findings, its labeling carries a boxed warning covering serious infections, malignancy, major cardiovascular events, blood clots, and death.

A large postmarketing safety trial known as ORAL Surveillance compared tofacitinib with tumor necrosis factor inhibitors in older rheumatoid arthritis patients who had cardiovascular risk factors, and it found higher rates of major cardiovascular events and cancers with tofacitinib, results that shaped its warnings and positioned it as a treatment generally reserved for use after other options ^[3]. Beyond its approved indications, the drug has been investigated for conditions such as plaque psoriasis, alopecia areata, vitiligo, and atopic dermatitis ^[2]. The most common side effects include upper respiratory infections, headache, diarrhea, and raised blood pressure, while more serious risks involve opportunistic infections, herpes zoster, and blood clots ^[3].

Tofacitinib is a prescription immunosuppressant and it dampens immune defenses, so it raises the risk of serious infections, including reactivation of herpes zoster. It carries boxed warnings for serious infections, certain cancers, major cardiovascular events, blood clots and death, based on a large safety study comparing it with tumor necrosis factor inhibitors. It can raise cholesterol and liver enzymes and lower blood counts, so regular monitoring is needed, and live vaccines are avoided during treatment.

Tofacitinib is metabolized mainly by CYP3A4 with a minor CYP2C19 contribution, and its interaction profile falls out of that split. Strong CYP3A4 inhibitors such as ketoconazole raise its exposure, and so does fluconazole, which is a moderate CYP3A4 inhibitor and a strong CYP2C19 inhibitor at once; the label flags that combination specifically. Strong inducers run the other way, and rifampin lowers tofacitinib exposure enough to lose the treatment effect, with carbamazepine, phenytoin and St John's wort acting similarly. Inhibitors of CYP2C19 alone, or of P-glycoprotein alone, do not shift it meaningfully.

The pharmacodynamic interaction is the one that causes harm. Tofacitinib blocks JAK1 and JAK3 signaling and suppresses immunity in its own right, so combining it with biologic DMARDs such as TNF inhibitors or abatacept, or with potent immunosuppressants like azathioprine, cyclosporine or tacrolimus, stacks that suppression and raises serious infection risk without buying extra efficacy. Live vaccines given during treatment carry a risk of disseminated infection for the same reason.

Checking a whole stack? Run it through interactions + stacks.

Tofacitinib was discovered by Pfizer in collaboration with the United States National Institutes of Health, originating from a research effort in the 1990s and 2000s to target the Janus kinase family of enzymes as a way to dampen overactive immune signaling. It was the first oral Janus kinase inhibitor to reach the market, receiving United States Food and Drug Administration approval in 2012 for rheumatoid arthritis under the brand name Xeljanz, a milestone that opened the era of small-molecule targeted therapies for autoimmune disease.

Its indications subsequently expanded to include psoriatic arthritis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis, and an extended-release formulation, Xeljanz XR, was introduced. A large post-authorization safety trial, ORAL Surveillance, later compared it against tumor necrosis factor inhibitors in an older, cardiovascular-risk-enriched population and found higher rates of major cardiovascular events and cancers, prompting boxed safety warnings. Tofacitinib nonetheless remains an important and widely studied representative of the JAK-inhibitor class.

Tofacitinib is a landmark medication, celebrated as the first oral Janus kinase inhibitor and the drug that ushered in a whole new class of targeted small-molecule therapies for autoimmune disease. For many patients with rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis, it offers meaningful control of symptoms in convenient pill form, a welcome alternative to injectable biologics, and its efficacy has been demonstrated across numerous randomized controlled trials, including a pivotal study in children with juvenile arthritis.

Its broad action on cytokine signaling is a genuine therapeutic strength. That same breadth, however, demands honesty about its risks: because JAK-STAT signaling governs immune defense, blood-cell production, and lipid handling, tofacitinib carries recognized concerns including infections, herpes zoster, and, in a large safety trial of higher-risk patients, elevated cardiovascular and cancer signals that led to boxed warnings. Used with appropriate patient selection and monitoring, it remains a valuable and influential option.